$538 MillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$11.49 - $53.50The lowest and highst price in the last 52 weeks.
-2.55xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$538 Million|
|Enterprise Value||$230 Million|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||-77.6%|
|Outstanding Shares||46.6 Million|
|Avg 30 Day Volume||1.08 Million|
|Earnings per Share||-$4.09|
|Price to Sales Ratio||Infinity|
|Price to Book Ratio||2.24|
|Revenue to Enterprise Value||10.23|
|EBIT to Enterprise Value||-1.08|
|Total Debt to Enterprise Value||0.0|
|Debt to Equity||0.0|
|Gross Profit||$22.5 Million|
|Net Income||-$211 Million|
|Quarterly Earnings Growth (YoY)||-16.5%|
|Return on Equity||-75.5%|
|Return on Assets||-50.1%|
|Return on Invested Capital||-61.56%|
CEO: Ali Tehrani
Industry: Pharmaceutical Preparation Manufacturing
Zymeworks Inc. (NYSE:ZYME) traded at $19.38 at close of the session on Monday, 11/29/21, made a downward move of -0.62% on its previous days price. Looking a...Stocks Register, about 2 months ago
Vanguard Group Inc. raised its stake in Zymeworks Inc. (NYSE:ZYME) by 26.8% during the second quarter, according to its most recent filing with the Securitie...Dakota Financial News, 2 months ago
No summary available.Seeking Alpha, 2 months ago
SVB Leerink restated their hold rating on shares of Zymeworks (NYSE:ZYME) in a report published on Monday, Price Targets.com reports. They currently have a $...Dakota Financial News, 2 months ago